1Kulaksizoglu IB. Mood and anxiety disorders in patients with myasthenia gravis: aetiology, diagnosis and treatment[J]. CNS Drugs, 2007, 21(6): 473- 481.
2Skeie GO, Apostolski S, Evoli A, et al. Guidelines for the treatment of autoirnmune neuromuscular transmission disorders[J]. Eur J Neurol, 2006, 13 (7): 691-699.
3Hilton-Jones D. When the patient fails to respond to treatment: myasthenia gravis [J]. Pract Neurol, 2007, 7(6): 405-411.
4Ciafaloni E, Massey JM, Tucker-Lipscornb B, et al. Mycophenolate mofetil for myasthenia gravis: an open-label pilot study[J]. Neurology, 2001, 56 (1) : 97-99.
5Draehman DB, Jones RJ, Brodsky RA. Treatment of refractory myasthenia: "rebooting" with high dose cyclophosphamide[J]. Ann Neurol, 2003, 53(1): 29- 34.
6Gladstone DE, Brannagan TH 3rd, Schwartzman RJ, et al. High dose cyclophosphamide for severe refractory myasthenia gravis[J]. chiatry, 2004, 75(5):789
7Lin PT, Martin BA, Weinacker AB, etal. High-dose cyclophosphamide in refractory myasthenia gravis with MuSK antibodies[J]. Muscle Nerve, 2006, 33 (3): 433-435.
8Shimojima Y, Matsuda M, Gono T, et al. Tacrolimus in refractory patients with myasthenia gravis: coadministration and tapering of oral prednisolone[J]. J Clin Neurosci, 2006, 13(1): 39-44.
9Prakash KM, Ratnagopal P, Puvanendran K, et al. Mycophenolate mofetil - as an adjunctive immunosup- pressive therapy in refractory myasthenia gravis: The Singapore experience[J]. J Clin Neurosci, 2007, 14 (3) : 278-281.
10Thakre M, Inshasi J, Marashi M. Rituximab in refractory MuSK antibody myasthenia gravis [J]. J Neurol, 2007, 254(7): 968-969.
